Human calreticulin can act as adjuvant in the maturation of antigen presenting cells by unknown
BioMed Central
Page 1 of 1
(page number not for citation purposes)
Cell Communication and Signaling
Open AccessMeeting abstract
Human calreticulin can act as adjuvant in the maturation of antigen 
presenting cells
A Bajor*1, J Hinrichs1, C Figueiredo1, M Wittmann2, R Blasczyk1 and B Eiz-
Vesper1
Address: 1Institute for Transfusion Medicine, Hannover Medical School, Hannover, Germany and 2Department of Dermatology and Allergology, 
Hannover Medical School, Hannover, Germany
* Corresponding author    
Calreticulin (CRT), an endoplasmic reticulum (ER) resi-
dent protein, is involved in critical cellular functions, such
as protein folding and antigenic peptide cross presenta-
tion. Furthermore, this chaperone has been proposed to
act as an adjuvant during the activation of dendritic cells
(DCs) in vivo. We assessed human eukaryotically
expressed CRT for its potential to induce NF-kappa B reg-
ulated maturation of monocyte-derived DCs. In order to
facilitate eukaryotic expression procedures, we established
and compared three different methods to express recom-
binant endotoxin-free CRT to be secreted in the superna-
tant of HEK 293 cells: (1.) the complete, unmodified CRT
coding sequence was cloned into the pcDNA3.1V5/His
vector (euCRT), (2.) the C-terminal ER-retrieval KDEL
amino acid sequence was mutated into KDQL in order to
disturb the endoplasmic retention and support the pro-
tein secretion (euCRT_KDQL) and (3.) a shRNA was
designed to knock down the expression of aminoacyl-
tRNA synthetase-interacting multifunctional protein-1
(AIMP-1), which is known to regulate protein retention in
the ER. An efficient shRNA sequence specific to AIMP-1
transcripts was delivered to HEK 293 cells, which were
afterwards transfected with the CRT-expressing vector
(euCRT). No relevant differences between these different
approaches were observed in regard to mRNA levels of the
transfected CRT determined by Real Time RT-PCR as well
as protein expression levels of CRT determined by V5/HIS
ELISA in the cell culture supernatants. Thus, for large scale
expression of CRT the first strategy with the unmodified
CRT sequence (euCRT) was chosen. The functional capa-
bility of the expressed calreticulin to induce maturation of
DCs was tested. By flow cytometry the translocation of
NF-kappa B into the nuclei of the monocytes after stimu-
lation with the recombinant CRT could be demonstrated.
Using low-dose CRT (10 μg/ml) the phenoptype of the
immature DCs changed to a more matured one, as indi-
cated by an increased surface expression of CD40, CD86,
CD83. In summary, our first data indicate, that this
recombinant CRT can act as an adjuvant for in vitro mat-
uration of DCs and therefore has the potential to assist in
T cell stimulation and expansion protocols.
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